AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 191 min read$CLBT

Barter David sold $136K of CLBT

Barter David (Chief Financial Officer) sold 12,134 shares of Cellebrite DI Ltd. (CLBT) at $11.21 ($0.14M total) on 2026-10-16.

Original reporting
SEC EDGAR · Barter David
Published Oct 19, 2026, 10:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CLBT
Neutral
high confidence
Mentioned
$CLBT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

A modest insider sell typically has limited price impact unless part of a larger trend.

02

Market read

Small insider sale; unlikely to move the stock significantly.

03

What to watch

Potential tax planning or portfolio rebalancing by the CFO.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 4 filings provide the first public disclosure of insider trades.

Company-level read

Ticker impact

$CLBTNeutralHigh confidence
Context

CFO Barter David sold 12,134 shares for $136K in an open‑market transaction disclosed on Form 4.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

Sale size is small relative to holdings; no 10b5‑1 plan; typical insider sell impact is limited.

Market effects

Sector

Minimal impact on the digital forensics sector; no broader industry signal.

Regional

US market only; no regional effect.

Global

Low; isolated insider transaction.

Counterpoint

What could challenge this read

The sale could be unrelated to fundamentals and may not affect price.

Key entities

  • company
    Cellebrite DI Ltd.

    Provider of digital intelligence solutions, listed on NASDAQ.

  • person
    Barter David

    Chief Financial Officer of Cellebrite.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CLBT insider trading history →

Related articles

AUG 20
$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

yahoo.com3 min
AUG 16
$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

simplywall.st6 min
AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min
AUG 14
$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

simplywall.st3 min